Zealand starts enrolment in Phase III trial of dasiglucagon for hypoglycemia
Denmark-based biotechnology firm Zealand Pharma has started patient enrolment in Phase III clinical trial of dasiglucagon to treat severe hypoglycaemia in diabetic patients.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Clinical Trials | Denmark Health | Diabetes | Endocrinology | New Zealand Health | Pharmaceuticals